CoChat
Sign Up
Cited by 489Schizophrenia research and treatmentTreatment of Major DepressionMental Health and Psychiatry

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.

Leucht, S, Arbter, D, Engel, R R, Kissling, W, Davis, J M·2009·Molecular Psychiatry
DOI 10.1038/sj.mp.4002136
Open this paper in CoChat — free account

Abstract

We conducted a systematic review and meta-analysis of randomized controlled trials that compared second-generation antipsychotic (SGA) drugs with placebo in schizophrenic patients and which considered 13 different outcome measures. Thirty-eight randomized controlled trials with 7323 participants were included. All SGA drugs were more effective than placebo, but the pooled effect size (ES) for overall symptoms (primary outcome) was moderate (-0.51). The absolute difference (RD) in responder rates was at 18% (41% responded to drug compared with 24% to placebo, number needed to treat=6). Similar ESs were found for the other efficacy parameters: negative symptoms (ES=-0.39), positive symptoms (ES=-0.48), depression (ES=-0.26), relapse (RD 20%) and discontinuation due to inefficacy (RD 17%). Curiously, the efficacy of haloperidol for negative and depressive symptoms was similar to that of the SGA drugs. In contrast to haloperidol, there was no difference in terms of EPS between any SGA drugs and placebo, and there was also no difference in terms of dropouts due to adverse events. Meta-regression showed a decline in treatment response over time, and a funnel plot suggested the possibility of publication bias. We conclude that the drug versus placebo difference of SGA drugs and haloperidol in recent trials was moderate, and that there is much room for more efficacious compounds. Whether methodological issues account in part for the relatively low efficacy ESs and the scarcity of adverse event differences compared with placebo needs to be established.

Overview

Integrity signals

Registry

Crossref · 10.1038/sj.mp.4002136

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 77 references

Research works printed but not linked: 4

  1. Adams CE, Coutinho E, Davis JH, Duggan L, Leucht S, Tharyan P, Cochrane Schizophrenia Group In: The Cochrane Library. John Wiley & Sons Ltd: Chichester, UK, 2007.
  2. Chouinard G, Ross-Chouinard A, Annable L, Jones BD . The extrapyramidal symptom rating scale. Can J Neurol Sci 1980; 7: 233.
  3. Honigfeld G . Clozapine: antipsychotic activity in treatment-resistant schizophrenics. Adv Ther 1984; 1: 77–97.
  4. Office of Clinical Pharmacology and Biopharmacy Review. Study Ris-USA-72. NDA number: 20272. Janssen-Cilag, Data on File 1996.

Cited by

Sorted by citations

Items 301–400 of 489

Related

See all

Metadata

Authors
Leucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M.
Affiliations
  • TUM Klinikum (DE)
  • Ludwig-Maximilians-Universität München (DE)
  • University of Illinois Chicago (US)
Corresponding author
Leucht, S
ORCID
Venue
Molecular Psychiatry
Publisher
Springer Science and Business Media LLC
Published
2008-01-08
Volume
14
Issue
4
Pages
429-447
ISSN
  • 1359-4184 (ISSN-L)
  • 1476-5578
DOI
10.1038/sj.mp.4002136
OpenAlex
W2021186654
Cited by
489
References
77
Citations by year
2026: 5 · 2025: 13 · 2024: 15 · 2023: 17 · 2022: 20 · 2021: 23 · 2020: 24 · 2019: 36 · 2018: 32 · 2017: 35 · 2016: 38 · 2015: 36 · 2014: 48 · 2013: 35 · 2012: 34
FWCI
3.25
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Molecular Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Keywords
atypical antipsychotics, schizophrenia, drug efficacy, haloperidol, negative symptoms, positive symptoms, depressive symptoms, relapse, extrapyramidal symptoms, adverse events, treatment response over time, publication bias
MeSH terms
Humans, Psychotic Disorders, Antipsychotic Agents, Randomized Controlled Trials as Topic, MEDLINE, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review